Statement of Changes in Beneficial Ownership (4)
August 26 2022 - 4:32PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Menzel Garry E |
2. Issuer Name and Ticker or Trading Symbol
TCR2 THERAPEUTICS INC.
[
TCRR
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President & CEO |
(Last)
(First)
(Middle)
C/O TCR2 THERAPEUTICS, 100 BINNEY STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/5/2022 |
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 7/5/2022 | | G | | 84527 | D | $0.00 | 0 (1) | I | See Footnote (1) |
Common Stock | 7/5/2022 | | G | | 84527 (1) | A | $0.00 | 84527 (1) | I | See Footnote (1) |
Common Stock | 7/5/2022 | | G | | 48202 | D | $0.00 | 132730 (2) | D (2) | |
Common Stock | 7/5/2022 | | G | | 48202 | A | $0.00 | 132729 (2) | I | See Footnote (2) |
Common Stock | 7/5/2022 | | G | | 132730 | D | $0.00 | 0 (3) | D (3) | |
Common Stock | 7/5/2022 | | G | | 132730 | A | $0.00 | 132730 (3) | I | See Footnote (3) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 84,527 shares of common stock held by the reporting person, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010, to the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 45, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust and may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust. |
(2) | The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 48,202 shares of common stock held by the reporting person to the Menzel Trust. |
(3) | The reporting person is voluntarily reporting the disposition for no consideration on July 5, 2022 of 132,730 shares of common stock held by the reporting person to the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own these securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Menzel Garry E C/O TCR2 THERAPEUTICS 100 BINNEY STREET CAMBRIDGE, MA 02142 | X |
| President & CEO |
|
Signatures
|
Margaret Siegel as Attorney-In-Fact | | 8/26/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Aug 2024 to Sep 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Sep 2023 to Sep 2024